Nexsan Exceeds First Quarter Revenue Target and Announces Plans to Foster More Growth and Continued Innovation on Marquee SAN and File Storage Product Line
10.5.2023 16:00:00 EEST | Business Wire | Press release
Nexsan today announced that it surpassed its aggressive Q1 earnings target. After being acquired by Serene Investment Management LLC in February, Serene’s ownership has quickly steered Nexsan back into a stage of growth, innovation, and profitability.
Under this new ownership, Serene Investment Management LLC’s first order of business was to bring in experienced technology leaders to foster a new era of growth and deliver on the ownership’s vision of continued high-quality product innovation, delivery, and unrivaled customer satisfaction. One of those experienced technology leaders is Nexsan’s new CEO, Dan Shimmerman, who has a proven track record of success in delivering strategic vision, execution, and value for all stakeholders in enterprise technology.
“The future is incredibly bright for all of Nexsan which includes our loyal customers and partners,” explains Nexsan CEO, Dan Shimmerman. “Serene’s ownership is committed to investing in the business and fueling continuous growth. We’ve been given the vital capital we need to continue to innovate and deliver the highly-reliable, cost-effective data storage solutions that have been exceeding specific and crucial business demands for over 20 years.”
As part of the acquisition earlier this year, Serene retained key employees and leaders to ensure business continuity and deliver on Nexsan’s commitment to a seamless customer support experience. Throughout the acquisition and restructuring, Serene has been steadfastly committed to maintaining Nexsan’s high level of customer support which includes the support team’s global coverage and footprint.
In the interim, Nexsan negotiated strong strategic alliance agreements with their global partner network to stabilize supply chains and kick-start its continued service to all end customers and vendors.
Earlier in the month of April, Nexsan also attended the NAB (National Association of Broadcasters) Show Centennial in Las Vegas, Nevada to showcase the reliability, cost-effectiveness, and continued innovation on its marquee SAN and file storage product line that includes E-Series, Unity, and the exciting developments on its Assureon Data Vault.
For more information on Nexsan’s suite of enterprise storage products, see https://www.nexsan.com/products-landing/.
For more information on Nexsan’s core use cases, see https://www.nexsan.com/whats-your-business/.
About Nexsan®
Nexsan® is a global leader in enabling customers to securely store, protect and manage data. Established in 1999, Nexsan has earned a reputation for delivering the most highly reliable, secure and cost-effective storage, while always remaining agile in order to continuously deliver purpose-built storage and data management solutions that meet complex and everchanging IT, business and budgetary requirements. Nexsan’s patented technology is ideal for a variety of use cases including Financial, Healthcare and Life Sciences, Government, Military, Law Enforcement, Education, Media and Entertainment and Call Centers. For further information, please visit: www.nexsan.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005029/en/
Contact information
Matthew Pugh
443-527-1552
mpugh@pughandtillerpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom